25 C
Vientiane
Saturday, May 31, 2025
spot_img
Home Blog Page 324

UK Clinical Study Finds Sky Labs’ Smart Ring ‘CART-I’ More Sensitive Than Apple Watch for AFib Detection

  • Published in the international journal Heart Rhythm O2, the clinical study demonstrates that CART-I achieved 84.6% sensitivity – higher than Apple Watch’s 69.1%

  • Sky Labs also recognized with Korea’s top tech honor: IR52 Jang Young-sil Award – Prime Minister’s Award

SEOUL, South Korea, April 21, 2025 /PRNewswire/ — Sky Labs, a health-tech startup based in South Korea, announced that its ring-shaped smart medical device, CART-I (Cardio Tracker), demonstrated higher sensitivity than the Apple Watch in detecting atrial fibrillation (AFib) in a recent clinical study. The study’s findings were published in Heart Rhythm O2, a peer-reviewed international journal.

Graphical Abstract, as published in Heart Rhythm O2
Graphical Abstract, as published in Heart Rhythm O2

“This study offers strong external validation of CART-I’s performance in detecting atrial fibrillation,” said Jack Lee, CEO of Sky Labs. “Together with CART BP, which focuses on hypertension management, these results demonstrate CART-I’s potential to support broader cardiovascular monitoring in the future. We will continue to develop medical devices that deliver both accuracy and convenience for patients.”

The comparative study, conducted across three hospitals in the UK (Oxford University Hospital, University Hospital Southampton, and Queen Elizabeth Hospital), involved approximately 500 patients and evaluated CART-I and Apple Watch under the same clinical protocol.

Researchers assessed the sensitivity and specificity of each device’s automatic AFib detection algorithms using single-lead electrocardiograms (SL-ECG) data, which was subsequently interpreted by physicians. Results showed that Sky Labs’ CART-I achieved 84.6% sensitivity, while Apple Watch recorded 69.1% under the same protocol. Both devices also demonstrated high performance in physician interpretation of SL-ECGs: the Apple Watch scored 95.4% sensitivity, and CART-I recorded 94.3%.

Unlike prior studies that focused solely on atrial fibrillation, this research is especially meaningful for its inclusion of a broad range of arrhythmias such as atrial flutter and atrial tachycardia.

Researchers noted, however, that wearable devices alone are not yet sufficient for diagnosing specific arrhythmias such as atrial flutter or atrial tachycardia. Physician interpretation remains essential, and automated algorithms should be considered as supportive tools rather than standalone diagnostic solutions.

Separately, Sky Labs’ cuffless ring-type blood pressure monitor, CART BP, was recently awarded the 2024 Prime Minister’s Prize at the IR52 Jang Young-sil Awards, one of Korea’s most prestigious recognitions for technological innovation. CART BP was selected for fulfilling all four key evaluation criteria: economic value, technological importance, originality, and technological independence.

CART BP is an innovative medical device that transforms traditional blood pressure monitoring by replacing cuff-based, intermittent arm measurements with comfortable, finger-based monitoring over a 24-hour period.

The device received regulatory approval from the Korean Ministry of Food and Drug Safety in 2023 and was approved for national health insurance reimbursement in 2024. As of April 2025, CART BP pro is in use at more than 1,300 hospitals and clinics across South Korea, supporting daily blood pressure monitoring and management.

About Sky Labs
Founded in September 2015, Sky Labs is a leading healthcare startup that has developed CART (Cardio Tracker), a ring-shaped medical device designed for disease monitoring using heart signals collected through optical sensors. Following this, the company developed CART BP, a cuffless, ring-shaped device that enables 24-hour blood pressure monitoring, providing valuable treatment information and making a groundbreaking contribution to improving the quality of life for hypertension patients. Sky Labs has signed an exclusive domestic distribution agreement for CART BP pro with South Korea’s Daewoong Pharmaceutical and is preparing for nationwide sales to hospitals, clinics, and general consumers.

Media Inquiries
Edelman Korea SkyLabs@edelman.com

CLAWLAB UNVEILS NEW CHAPTER OF INNOVATIVE TUFTING TOOLS DESIGNED TO MAKE HOME CRAFTING A BREEZE

Aimed at makers, crafters, DIY’ers, artists & studios, Clawlab’s tufting tools make out-of-the-box rug making, crafting, & art a reality for beginners or pros alike

LOS ANGELES, April 21, 2025 /PRNewswire/ — Clawlab — the innovative brand at the intersection of textile art and technology — is proud to announce the official launch of its highly anticipated Tufting Gun H1 and Tufting Frame H1. Following their successful crowdfunding campaign, and after months of continued development and listening closely to the needs of creators worldwide the updated Gun and Frame are set to help make tufting the next big trend through its ease of use, and appeal to beginners and professionals alike with its ‘toy-like’ ease of use that produces professional results.

Founded in 2023 by a textile robotics enthusiast, Clawlab has quickly established itself as a pioneer in reimagining tools for the next generation of artisans, hobbyists, and creative technologists. These new releases reflect the company’s mission to simplify and modernize the creative process, making tufting more accessible, efficient, and enjoyable for everyone. Clawlab also aims to cater to tufting enthusiasts through enhanced after-sales support, product tutorials, and ongoing improvements to meet users’ demands.


Clawlab – Where Technology Meets Craftsmanship

The Tufting Gun H1 and Frame H1 are meticulously engineered to elevate the tufting experience, whether you’re a seasoned textile artist or just getting started. With a focus on safety, precision, and ease of use, these tools are designed to empower creators while eliminating common frustrations in the tufting process and come ready to use, with no more sourcing parts or pieces to make a tufting kit. Both the Tufting Gun H1 and Tufting Frame H1 feature upgrades based on direct feedback from users, including an upgraded frame to aid beginners as well as an additional accessory designed to keep the yarn from slipping out of the gun. 

Tufting Gun H1 Product Highlights

-Precision Control: Adjustable speed settings paired with illuminated feedback for flawless results.
-Enhanced Safety: An enclosed mechanism with automatic standby mode ensures worry-free operation.
-Lightweight & Ergonomic: Weighing just 550g, it reduces fatigue and minimizes vibration for longer, more comfortable sessions.
-Built to Last: Durable, low-maintenance design with long-term reliability in mind.

Tufting Frame H1 Product Highlights

-Nail-Free Design: Safe, approachable, and suitable for creators of all skill levels.
-Exceptional Stability: Four vertical support rods deliver eight times the stability of standard frames.
-Effortless Tensioning: A planetary gear system reduces fabric tensioning effort by 75%.
-Continuous Workflow: A unique fabric rod system makes project transitions seamless and uninterrupted.

As tufting rises from niche craft to a celebrated medium of self-expression, especially among Gen Z and young creators, Clawlab’s latest innovations answer the call for tools that are not only functional but also thoughtfully designed for modern makers. These products aim to inspire, empower, and streamline the tufting experience across art, fashion, and interior design.

Both the Tufting Gun H1 and Frame H1 will be available for purchase starting April 21, exclusively at Clawlab.com.

Stay connected with Clawlab! Follow us on Instagram: @clawlab_official, Facebook: HelloCLAWLAB, and join our CLAWLAB Tufting Group, subscribe on YouTube: @Clawlab_official, and find us on TikTok: @clawlab_official. For inquiries, email us at marketing@clawlabtech.com

Tuffing in Your Hand, Chill in Your Life. – The Clawlab Team.

About Clawlab

At Clawlab, we believe everyone should have the opportunity to express their emotions through creativity. Our founder, an innovator at the intersection of technology and art, is passionate about merging these worlds. With extensive experience in the tech industry and a deep love for handcrafted creation, he founded Clawlab in 2023, inspired by the collision of textiles and robotics. Clawlab is more than just a technology brand; it’s a platform empowering artists with professional tools that simplify the creative process. Our tufting tools are designed for artists who may not be familiar with tufting but possess great ideas. We strive to be their creative partner, continuously refining our products through collaboration, allowing creators to focus on their vision and truly enjoy the making process.

LightInTheBox Announces Positive Customer Feedback and Return to Profitability with New Direct-to-Consumer Brand

SINGAPORE, April 21, 2025 /PRNewswire/ — LightInTheBox Holding Co., Ltd. (NYSE: LITB) (“LightInTheBox” or the “Company”), a global online retail company, today announced that it has received positive feedback from customer surveys regarding one of its newly launched Direct-to-Consumer (DTC) brands. The brand has achieved an average Net Promoter Score (NPS) of 60, surpassing the industry average for Consumer Services / Catalog / Specialty Distribution, indicating a strong initial reception from customers.

Customer Praise for Quality and Service

Customer testimonials highlight the brand’s high-quality products and exceptional customer service. Reviewers have praised the apparel for its “stunning colors and perfect fit,” with one customer noting, “These dresses fit me like one big beautiful glove!” The materials have been commended as “beautiful and lightweight,” while the customer service has been characterized as “superior.”

Strategic Shift Drives Profitability

This positive feedback underscores the success of LightInTheBox’s strategic shift towards proprietary DTC brands, which has been instrumental in the Company’s return to profitability. By focusing on in-house design and manufacturing, LightInTheBox has been able to deliver higher-quality products and a more personalized customer experience, setting it apart from its traditional business model. This shift has not only enhanced customer satisfaction but has also improved the Company’s financial performance, enabling it to achieve profitability in recent quarters.

A More Attractive Business Model

The new DTC approach represents a significant evolution from LightInTheBox’s traditional business model. By controlling the entire value chain—from design to delivery—the Company has increased its operational efficiency and customer loyalty. This model has proven to be more appealing to both consumers and investors, as it allows for faster innovation, a direct connection with customers, and sustainable financial success.

Leadership Perspective

“We are thrilled with the positive response from our customers to this new DTC brand,” said Mr. Jian He, CEO of LightInTheBox. “This success is a testament to our strategic vision and the hard work of our team. More importantly, it has played a key role in our return to profitability, and we are confident that this momentum will continue as we expand our portfolio of proprietary brands.”

Future Growth on the Horizon

Looking ahead, LightInTheBox plans to launch additional proprietary brands and leverage advanced technologies, such as AI, to further enhance its offerings and operational efficiency. With a strong foundation in manufacturing and a customer-centric approach, the Company is well-positioned to capitalize on the growing demand for affordable, high-quality lifestyle products.

About LightInTheBox Holding Co., Ltd.

LightInTheBox is a global specialty retail company, providing a diverse range of affordable lifestyle products directly to consumers worldwide since 2007. In 2024, the Company shifted its focus to apparel design and launched its first proprietary brand, Ador.com, to meet the growing global demand for accessible higher-end fashion. Ador.com specializes in designer-quality clothing for women aged 35-55 at competitive prices and operates design studios and sample shops in both the U.S. and China, including a boutique and design studio in Campbell, California. Additionally, LightInTheBox offers a comprehensive suite of services to e-commerce companies, including advertising, supply chain management, payment processing, order fulfillment, and shipping and delivery solutions. For more information, please visit https://ir.ador.com.

Safe Harbor Statement

This press release contains forward-looking statements that involve risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets” and similar statements. Among other things, statements that are not historical facts, including statements about LightInTheBox’s beliefs and expectations, the business outlook and quotations from management in this announcement, as well as LightInTheBox’s strategic and operational plans, are or contain forward-looking statements. LightInTheBox may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: LightInTheBox’s goals and strategies; LightInTheBox’s future business development, results of operations and financial condition; the expected growth of the global online retail market; LightInTheBox’s ability to attract customers and further enhance customer experience and product offerings; LightInTheBox’s ability to strengthen its supply chain efficiency and optimize its logistics network; LightInTheBox’s expectations regarding demand for and market acceptance of its products; competition; fluctuations in general economic and business conditions and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in LightInTheBox’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and LightInTheBox does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Investor Relations Contact

Investor Relations
LightInTheBox Holding Co., Ltd.
Email: ir@ador.com

Jenny Cai
Piacente Financial Communications
Email: ador@tpg-ir.com

Brandi Piacente
Piacente Financial Communications
Tel: +1-212-481-2050
Email: ador@tpg-ir.com

INTCO Medical Launches New Syntex™ Synthetic Disposable Latex Gloves Featuring Breakthrough Performance Beyond Natural Latex

ZIBO, China, April 21, 2025 /PRNewswire/ — INTCO Medical (“INTCO” or “the Company”), the world’s leading manufacturer of disposable gloves, has announced the global launch of its exclusive patented Syntex™ Synthetic Disposable Latex Gloves product. Breaking natural latex boundaries, Syntex™ redefines glove quality, safety, and performance.


Syntex™ Synthetic Latex (Exam) Gloves Outperforms Latex, Outperforms Costs

Syntex™ gloves have passed EN455 and EN374 testing and are fully compliant with FDA and EU CE standards, ensuring safety and reliability across a wide range of industries, including healthcare, food processing, and industrial protection.

Unlike traditional latex gloves, the new Syntex™ gloves offer high elasticity, strong puncture and chemical resistance, and a natural-latex-like feel, all while avoiding the allergy risks associated with natural latex. Developed with an exclusive innovative formula that increases average breaking elongation through a 650% stretch, meeting the ASTM D6319 medical glove standard and offering exceptional durability and comfort.

Syntex™ is free of natural latex proteins, drastically reducing allergy risks and cutting reliance on natural rubber plantations. This helps protect tropical rainforest ecosystems and aligns with the European Union’s Regulation on Deforestation-free Products (EUDR). With EUDR enforcement requiring geolocation-based traceability, companies face significant compliance pressure. Syntex™’s composition removes such risks by excluding EUDR-controlled natural latex sources, helping global buyers adapt with confidence.

As regulatory demands rise and natural rubber supply chains face increasing volatility, Syntex™ provides a practical alternative by offering stable pricing and shorter order cycles. The product supports ESG-focused procurement while improving supply chain resilience.

Mr. Fangyi Liu, chairman with INTCO, commented: “Syntex™ embodies years of technological expertise and innovative R&D from INTCO, setting a new standard in the glove industry. Through advanced technology and responsible manufacturing, we’re helping global partners meet evolving performance and sustainability goals.”

With over 30 years of experience, INTCO Medical has developed a vertically integrated production system that leverages proprietary technology and intelligent infrastructure, making it China’s largest disposable glove manufacturer and the world’s largest supplier of non-natural rubber gloves.

About INTCO Medical

INTCO Medical is the world’s leading manufacturer of disposable gloves. As a high-tech manufacturing company, INTCO specializes in the R&D, production, and marketing of medical consumables and durable medical equipment. The company’s core business segments include medical consumables, rehabilitation equipment, and physiotherapy care. These products have been exported to more than 120 countries and regions in America, Europe, Asia, Africa and Oceania, providing practical products and high-quality services to over 10,000 clients. https://www.intcomedical.com/

KOREAN LENDERS AND OCEAN WEST CAPITAL PARTNERS FORECLOSE ON MIDTOWN MANHATTAN OFFICE BUILDING

NEW YORK, April 21, 2025 /PRNewswire/ — Ocean West Capital Partners (“Ocean West”) led the successful UCC foreclosure of 285 Madison Avenue last week, a 511,000 square-foot office property primely located in Midtown Manhattan near Grand Central Terminal. Ocean West represented the mezzanine lender, which was comprised of a consortium of some of the largest insurance companies in South Korea.

KOREAN LENDERS AND OCEAN WEST CAPITAL PARTNERS FORECLOSE ON MIDTOWN MANHATTAN OFFICE BUILDING
KOREAN LENDERS AND OCEAN WEST CAPITAL PARTNERS FORECLOSE ON MIDTOWN MANHATTAN OFFICE BUILDING

While the property remains well leased and in one of the top performing submarkets in the U.S., Midtown Manhattan, the loan fell into maturity default in late 2022. Originally the loan was extended to provide time for recovery, but it came back into default in late 2024 when the extension expired. Ocean West was brought in at this time to serve as advisor to the Korea-based mezzanine lender and evaluate various debt recovery strategies.

With Manhattan office leasing trends improving dramatically and increased investment activity in the market, the mezzanine lender concluded that its strongest course of action was to exercise its foreclosure rights and invest new capital to take control of the property. Ocean West will remain involved throughout the investment hold period to oversee the asset. 

“We believe that the quality of the building, the vibrancy of the market, and our cost basis will provide a strong opportunity to enhance cashflows and create value over time,” indicated Ryan Tucker, Principal at Ocean West. The property boasts a desirable Madison Avenue address just one block from Grand Central Terminal, and during a recent renovation, over $80 million was invested in the property to fully modernize the building and enhance the amenity program, which includes a rooftop deck and event space, conferencing center, and onsite gym.

The acquisition of 285 Madison through UCC foreclosure is part of more than $2 billion of New York City assets upon which Ocean West has either acquired or advised upon for Korean institutional investors in the past 12 months.  “We have seen a change in tenor from the Korean lending community whereby they have become more aggressive in protecting assets located in strong markets. These investors represent some of the largest insurance companies and pension funds in the world, who have capital to execute a wide variety of strategies”, said Phil Choi, Principal and Co-Founder of Ocean West. 

DLA Piper LLP represented the mezzanine lender throughout the process and was instrumental in formulating and executing the foreclosure strategy. Newmark managed the UCC auction marketing process, and Daol Asset Management served as the Korean investment advisor for this transaction.

For office leasing inquiries, please contact Daniel Levine (daniel.levine@nmrk.com) and Dylan Weisman (dylan.weisman@nmrk.com) at Newmark.

For retail leasing inquiries, please contact Adam Weinblatt (adam.weinblatt@nmrk.com) and Jason Pruger (jason.pruger@nmrk.com) at Newmark.

Ocean West Capital Partners is a full-service real estate investment and management platform dedicated to identifying and executing opportunities that create long-term value for its partners and investors. Since its founding in 2010, Ocean West has acquired and operated industrial, office, and residential investments, completing over $8.5 billion in commercial real estate transactions.

For press information please contact John Weiss, 213-784-1131, jweiss@oceanwestcp.com

Photo – https://laotiantimes.com/wp-content/uploads/2025/04/ocean_west_capital_partners_manhattan.jpg

Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension

SHANGHAI, April 21, 2025 /PRNewswire/ — Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT), has been approved by China’s National Medical Products Administration (NMPA).

RN1871 is designed to silence AGT mRNA expression in the liver, precisely inhibiting the production of the key precursor protein in the Renin-Angiotensin-Aldosterone System (RAAS). The RAAS pathway plays a key role in blood pressure regulation, and its overactivation is closely linked to the progression of hypertension. Preclinical studies have demonstrated that RN1871 delivers long-lasting blood pressure control offering a promising new therapeutic option for over 1.5 billion hypertension patients worldwide.

Stella Shi, CEO and Founder of Rona Therapeutics, stated: “The IND approval of RN1871 marks a significant breakthrough in our pursuit of innovative therapies for chronic diseases. By leveraging siRNA technology to treat disease fundamentally, RN1871 achieves sustained efficacy with less dosing frequency. We look forward to bringing this innovative therapy to hypertension management where more compliant and safe treatment is needed to improve cardiovascular events and other comorbidities.”

Dr. Alex M. DePaoli, Chief Medical Officer and Executive Vice President of Translational Medicine, added: “RN1871’s preclinical data showed potent AGT suppression which reduces blood pressure significantly with a favorable safety profile. We plan to advance RN1871 into Phase I trials to evaluate its safety, pharmacokinetics, and preliminary efficacy in humans. This progress reflects our team’s expertise in translating scientific insights into clinical solutions.”

About Rona Therapeutics
Rona Therapeutics is a global leader in nucleic acid therapeutics discovery and development, specializing in the treatment of cardiometabolic and neurological diseases. Rona Therapeutics is committed to developing the best and first-in-class siRNA drugs with differentiation and innovation to address unmet needs and improve outcome in cardiovascular diseases, obesity, MASH and neurological diseases through both hepatic and extra-hepatic delivery of proprietary siRNA.

For Further information,Please visit: www.ronatherapeutics.com or contact: BD@ronatherapeutics.com

Recurrent Energy Announces Successful Operation of 127 MW Solar Project in Louisiana

KITCHENER, ON, April 21, 2025 /PRNewswire/ — Recurrent Energy, a subsidiary of Canadian Solar Inc. (“Canadian Solar”) (NASDAQ: CSIQ), and a global developer, owner, and operator of solar and energy storage assets, held a tour and ribbon cutting ceremony at Bayou Galion Solar, a 127 MWdc solar project located in Northeast Louisiana. The project commenced operations in November 2024.

Solar energy investments in Louisiana are growing, driven by increasing demand for electricity from manufacturing and data centers. By the end of 2024, cumulative solar investment in Louisiana reached more than $2 billion[1].

To celebrate the project’s commercial operation, Recurrent Energy welcomed local leaders to the site in Morehouse Parish for a guided tour and ribbon cutting ceremony. Bayou Galion Solar generates enough electricity to power the equivalent of approximately 20,500 homes annually while providing a substantial source of new tax revenue for the local community. In connection with the event, Recurrent Energy is also making a donation to the Cotton Country Players, a local theatre group, in support of the nearby historic Rose Theatre.

Dorothy Ford, Executive Director of the Bastrop-Morehouse Chamber of Commerce, said, “Solar energy creates a positive impact on its community. From creating jobs to generating local revenue, we at the Bastrop-Morehouse Chamber of Commerce recognize the importance of what Bayou Galion Solar is contributing to our economic growth.”

Kay King, CEO of Morehouse Economic Development Corporation, added, “Congratulations to Recurrent Energy on the completion of the Bayou Galion Project. Solar development in our parish improves our tax base, adds income to landowners, and diversifies our area’s electrical power sources. Morehouse Parish supports this development, which is building a foundation for a strong electrical grid system that will power future growth here and across our region.”

Jeffrey Clark, President of Advanced Power Alliance, said, “Bayou Galion is a state-of-the-art energy investment that will help provide Louisiana with affordable power to benefit every consumer in the state. Morehouse Parish has a long and storied history in energy, and it’s a real thrill and a tremendous honor to celebrate with neighbors and community leaders as this parish steps boldly into a new and expanded energy economy.  With tax revenue for local schools and governments, and clean affordable power for consumers, Bayou Galion is a winner for Louisianans near and far.”

Ismael Guerrero, CEO of Recurrent Energy, emphasized, “The successful completion of Bayou Galion Solar marks a significant milestone for Recurrent Energy—our first project in Louisiana. This $160 million investment not only brings clean, reliable power to the region, but also drives local economic development, creates jobs, and strengthens the state’s energy infrastructure. We are honored by the trust placed in us by Morehouse Parish. Louisiana has long been an energy leader. We look forward to deepening our partnerships as we develop and operate projects across the state.”

Recurrent Energy previously announced that Mitsubishi UFJ Financial Group, Inc. (MUFG) acted as Coordinating Lead Arranger for the project financing totaling $160 million. Primoris Renewables Energy, Inc. completed construction of Bayou Galion Solar with the support of local vendors.

About Recurrent Energy

Recurrent Energy, a subsidiary of Canadian Solar Inc., is one of the world’s largest and most geographically diversified utility-scale solar and energy storage project development, ownership, and operations platforms. With an industry-leading team of in-house energy experts, Recurrent Energy serves as Canadian Solar’s global development and power services business. To date, Recurrent Energy has successfully developed, built, and connected 11 GWp of solar projects and more than 3 GWh of energy storage projects across six continents. As of December 2024, its project development pipeline includes over 25 GWp of solar and 75 GWh of energy storage capacity.

About Canadian Solar Inc. 

Canadian Solar is one of the world’s largest solar technology and renewable energy companies. Founded in 2001 and headquartered in Kitchener, Ontario, the Company is a leading manufacturer of solar photovoltaic modules; provider of solar energy and battery energy storage solutions; and developer, owner, and operator of utility-scale solar power and battery energy storage projects. Over the past 24 years, Canadian Solar has successfully delivered nearly 150 GW of premium-quality, solar photovoltaic modules to customers across the world. Through its subsidiary e-STORAGE, Canadian Solar has shipped over 10 GWh of battery energy storage solutions to global markets as of December 31, 2024, boasting a US$3.2 billion contracted backlog as of December 31, 2024. Since entering the project development business in 2010, Canadian Solar has developed, built, and connected approximately 11.5 GWp of solar power projects and 4.5 GWh of battery energy storage projects globally. Its geographically diversified project development pipeline includes 25 GWp of solar and 75 GWh of battery energy storage capacity in various stages of development. Canadian Solar is one of the most bankable companies in the solar and renewable energy industry, having been publicly listed on the NASDAQ since 2006. For additional information about the Company, follow Canadian Solar on LinkedIn or visit www.canadiansolar.com.

Canadian Solar Inc. Investor Relations Contact
Wina Huang
Investor Relations
Canadian Solar Inc.
investor@canadiansolar.com 

Recurrent Energy Media Inquiries
Inés Arrimadas
Recurrent Energy
comm_@recurrentenergy.com 

Acepodia Presents Preclinical Data on Antibody-Dual-Drugs Conjugation (AD2C) technology at AACR Annual Meeting 2025

ALAMEDA, Calif. and TAIPEI, April 21, 2025 /PRNewswire/ — Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C) for hepatocellular carcinoma (HCC). The data will be featured at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will take place from April 25 to April 30, 2025 in Chicago, Illinois.

The poster presentation, titled “Development of dual-payload anti-GPC3 antibody-drug conjugate by dual-payload antibody conjugation (AD2C) platform for hepatocellular carcinoma treatment,” showcases the company’s next-generation ADC generated using Acepodia’s AD2C platform. This platform allows for the conjugation of two distinct payloads to a single antibody without the need of antibody engineering or enzymatic conjugation. AD2C, carrying payloads with different mechanisms of action, offer enhanced therapeutic potency by targeting diverse cell populations in heterogeneous tumors or overcoming resistance to single-payload therapy.

Presentation Details:

Session Title: Novel Drug Delivery Technologies
Session Category: Experimental and Molecular Therapeutics
Date and Time: April 28, 2025 | 9:00 AM12:00 PM CDT
Location: McCormick Place Convention Center, Chicago, IL
Poster Board Number: 4 | Poster Section: 23
Abstract Number: 1785

“Acepodia’s dual-payload ADC approach is designed to address key limitations of current single-payload therapies,” said Dr. Sonny Hsiao, Chairman and CEO of Acepodia. “By combining targeted delivery with enhanced cytotoxicity, this platform holds promise for more effective treatment of liver cancer and other solid tumors.” AD2C platform provides a novel, antibody-engineering-free approach to generate dual-payload ADCs, offering a potential solution to tumor heterogeneity and drug resistance in cancer treatment.

The company’s AD2C pipeline is part of its broader portfolio of conjugation technologies derived from the laboratory of Nobel Laureate Dr. Carolyn Bertozzi, enabling the site-specific delivery of therapeutic payloads using bioorthogonal click chemistry.

About Acepodia

Acepodia (6976.TT) is a clinical-stage biotechnology company headquartered in Taipei and Alameda, California, advancing innovative cancer and autoimmune disease therapies. The company’s proprietary platforms leverage novel cell-based and antibody conjugation technologies to deliver potent, targeted, and safer therapies. Its conjugation platforms—originating from the lab of Nobel Laureate Carolyn Bertozzi—enable precise linking of antibodies or immune cells with cytotoxic payloads using click chemistry, creating a unique therapeutic potential for various cancer types and autoimmune diseases.

For more information, visit https://www.acepodia.com/